Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Koji AbeDepartment of Neurology, Okayama University Hospital, OkayamaCorrespondence[email protected]

Yasuto ItoyamaDepartment of Neurology, Tohoku University Hospital, Sendai (Yasuto Itoyama is currently affiliated with International University of Health and Welfare, Ohtawara, Japan)

Gen SobueDepartment of Neurology, Nagoya University Hospital, Nagoya

Shoji TsujiDepartment of Neurology, The University of Tokyo Hospital, Tokyo

Masashi AokiDepartment of Neurology, Tohoku University Hospital, Sendai (Yasuto Itoyama is currently affiliated with International University of Health and Welfare, Ohtawara, Japan)

Manabu DoyuDepartment of Neurology, Aichi Medical University Hospital, Nagakute

Chikuma HamadaFaculty of Engineering, Tokyo University of Science, Tokyo

Kazuoki KondoDevelopment Division, Mitsubishi Tanabe Pharma Corporation, Tokyo

Takatomo YoneokaDevelopment Division, Mitsubishi Tanabe Pharma Corporation, Tokyo

Makoto AkimotoDevelopment Division, Mitsubishi Tanabe Pharma Corporation, Tokyo

Hiide YoshinoYoshino Neurology Clinic, Ichikawa, Japan

& on behalf of The Edaravone ALS Study Group show all

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date